Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Miller, R. T.
Right arrow Articles by Cattley, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, R. T.
Right arrow Articles by Cattley, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 21, No. 4, 647-652, April 2000
© 2000 Oxford University Press

Carcinogenesis

Apoptosis, mitosis and cyclophilin-40 expression in regressing peroxisome proliferator-induced adenomas

Richard T. Miller2, Steven P. Anderson1, J.Christopher Corton1 and Russell C. Cattley1

North Carolina State University College of Veterinary Medicine, 4700 Hillsborough Street, Raleigh, NC 27606 and
1 Chemical Industry Institute of Toxicology, 6 Davis Drive, PO Box 12137, Research Triangle Park, NC 27709, USA

Chronic exposure to peroxisome proliferators (PP), including certain industrial and pharmaceutical chemicals, causes liver cancer in rodents. Continuous exposure to PP is needed for tumor development since the frequency of hepatocellular neoplasms is decreased in animals returned to control diet. To determine cellular and molecular events responsible for enhanced growth in PP-induced liver tumors, we evaluated the relationships of WY-14,643 levels, apoptosis, mitosis and cyclophilin-40 (Cyp-40) expression in regressing tumors induced by WY-14,643, a potent PP. Male F344 rats were fed WY-14,643 (0.1%) in the diet for 43 weeks and then switched to control diet for 2, 3, 5 or 36 days. Mean serum and hepatic concentrations of WY-14,643 were decreased as early as 2 days following removal of WY-14,643 as compared with rats continuously fed WY-14,643. Adenomas from rats maintained on WY-14,643 markedly compressed surrounding parenchyma. Evidence of adenoma regression was observed by 3 days of WY-14,643 withdrawal and was characterized by loss of compression. Decreased compression corresponded to increases in the apoptotic index and decreases in the mitotic index in regressing adenomas at 2, 3, and 5 days following the switch to control diet. Cyclophilins are multifunctional receptor proteins involved in numerous signal transduction pathways, including those mediated by cyclosporin, a liver tumor promoter in rats. Cyp-40 expression was markedly increased in adenomas from continuously exposed rats, but expression returned to levels similar to surrounding parenchyma in adenomas after 5 days of WY-14,643 withdrawal. Taken together, these results indicate that WY-14,643-induced adenomas regress rapidly following withdrawal of the PP in association with declining liver WY-14,643 levels, suggesting that peroxisome proliferator-activated receptor {alpha} may mediate PP-induced alterations in mitogenic and/or apoptotic regulation in growing tumors, in conjunction with alterations in Cyp-40 signal transduction.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
S. P. Anderson, C. Dunn, A. Laughter, L. Yoon, C. Swanson, T. M. Stulnig, K. R. Steffensen, R. A.S. Chandraratna, J.-A. Gustafsson, and J. C. Corton
Overlapping Transcriptional Programs Regulated by the Nuclear Receptors Peroxisome Proliferator-Activated Receptor {alpha}, Retinoid X Receptor, and Liver X Receptor in Mouse Liver
Mol. Pharmacol., December 1, 2004; 66(6): 1440 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Strakova, J. Ehrmann, P. Dzubak, J. Bouchal, and Z. Kolar
The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-{gamma} Ciglitazone Affects Human Glioblastoma Cell Lines
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1239 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
R. C. Cattley
Peroxisome Proliferators and Receptor-Mediated Hepatic Carcinogenesis
Toxicol Pathol, February 1, 2004; 32(2_suppl): 6 - 11.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
C. Michel, C. Desdouets, B. Sacre-Salem, J.-C. Gautier, R. Roberts, and E. Boitier
Liver Gene Expression Profiles of Rats Treated with Clofibric Acid: Comparison of Whole Liver and Laser Capture Microdissected Liver
Am. J. Pathol., December 1, 2003; 163(6): 2191 - 2199.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
S. P. Anderson, C. S. Dunn, R. C. Cattley, and J.C. Corton
Hepatocellular proliferation in response to a peroxisome proliferator does not require TNF{alpha} signaling
Carcinogenesis, November 1, 2001; 22(11): 1843 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
R. T. Miller, L. A. Scappino, S. M. Long, and J. C. Corton
Role of Thyroid Hormones in Hepatic Effects of Peroxisome Proliferators
Toxicol Pathol, January 1, 2001; 29(1): 149 - 155.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.